CN101060860B - 用于治疗抑郁症的包含选择性5-羟色胺再摄取抑制剂和糖皮质激素受体拮抗剂的药物组合 - Google Patents
用于治疗抑郁症的包含选择性5-羟色胺再摄取抑制剂和糖皮质激素受体拮抗剂的药物组合 Download PDFInfo
- Publication number
- CN101060860B CN101060860B CN2005800395147A CN200580039514A CN101060860B CN 101060860 B CN101060860 B CN 101060860B CN 2005800395147 A CN2005800395147 A CN 2005800395147A CN 200580039514 A CN200580039514 A CN 200580039514A CN 101060860 B CN101060860 B CN 101060860B
- Authority
- CN
- China
- Prior art keywords
- depression
- pharmaceutically acceptable
- treatment
- ssri
- serotonin reuptake
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 title claims abstract description 42
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 title claims abstract description 41
- 238000011282 treatment Methods 0.000 title claims description 20
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 title claims description 9
- 208000020401 Depressive disease Diseases 0.000 title claims description 4
- 239000000890 drug combination Substances 0.000 title description 4
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 239000012453 solvate Substances 0.000 claims abstract description 12
- 239000003937 drug carrier Substances 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 19
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 229960002464 fluoxetine Drugs 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 abstract description 27
- 238000002560 therapeutic procedure Methods 0.000 abstract description 6
- 230000000694 effects Effects 0.000 description 21
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 102000007527 Autoreceptors Human genes 0.000 description 5
- 108010071131 Autoreceptors Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000000586 desensitisation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000001690 micro-dialysis Methods 0.000 description 3
- DFELGYQKEOCHOA-BZAFBGKRSA-N (8s,11r,13s,14s,17s)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=C1 DFELGYQKEOCHOA-BZAFBGKRSA-N 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229960001653 citalopram Drugs 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 210000002442 prefrontal cortex Anatomy 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 239000002438 stress hormone Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- -1 S-citalopram Chemical compound 0.000 description 1
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 229920002472 Starch Chemical class 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 208000022371 chronic pain syndrome Diseases 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 239000008107 starch Chemical class 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310257884.4A CN103316019B (zh) | 2004-11-19 | 2005-11-16 | 用于治疗抑郁症的包含选择性5-羟色胺再摄取抑制剂和糖皮质激素受体拮抗剂的药物组合 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04257199.2 | 2004-11-19 | ||
EP04257199 | 2004-11-19 | ||
PCT/EP2005/056023 WO2006053884A1 (en) | 2004-11-19 | 2005-11-16 | Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310257884.4A Division CN103316019B (zh) | 2004-11-19 | 2005-11-16 | 用于治疗抑郁症的包含选择性5-羟色胺再摄取抑制剂和糖皮质激素受体拮抗剂的药物组合 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101060860A CN101060860A (zh) | 2007-10-24 |
CN101060860B true CN101060860B (zh) | 2013-07-17 |
Family
ID=34930815
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310257884.4A Expired - Fee Related CN103316019B (zh) | 2004-11-19 | 2005-11-16 | 用于治疗抑郁症的包含选择性5-羟色胺再摄取抑制剂和糖皮质激素受体拮抗剂的药物组合 |
CN2005800395147A Expired - Fee Related CN101060860B (zh) | 2004-11-19 | 2005-11-16 | 用于治疗抑郁症的包含选择性5-羟色胺再摄取抑制剂和糖皮质激素受体拮抗剂的药物组合 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310257884.4A Expired - Fee Related CN103316019B (zh) | 2004-11-19 | 2005-11-16 | 用于治疗抑郁症的包含选择性5-羟色胺再摄取抑制剂和糖皮质激素受体拮抗剂的药物组合 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20080255074A1 (zh) |
EP (2) | EP1814589B1 (zh) |
JP (2) | JP5569949B2 (zh) |
CN (2) | CN103316019B (zh) |
AU (1) | AU2005305882B2 (zh) |
BR (1) | BRPI0517847A (zh) |
CA (1) | CA2585317C (zh) |
IL (1) | IL182768A (zh) |
MX (1) | MX2007006045A (zh) |
WO (1) | WO2006053884A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011338428B2 (en) | 2010-12-07 | 2015-05-21 | Allison Transmission, Inc. | Energy storage system for hybrid electric vehicle |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1173330A (zh) * | 1996-06-19 | 1998-02-18 | 阿克佐诺贝尔公司 | 含米尔塔扎平和一种或多种选择性5-羟色胺再摄取抑制剂的药物组合物 |
WO2003037354A1 (en) * | 2001-10-26 | 2003-05-08 | Akzo Nobel N.V. | USE OF (11β, 17β)-11-(1,3-BENZODIOXOL-5-YL)-17-HYDROXY-17-(1-PROPYNYL)-ESTRA-4,9-DIEN-3-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER |
WO2004030618A2 (en) * | 2002-09-24 | 2004-04-15 | Combinatorx, Incorporated | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030162695A1 (en) * | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
-
2005
- 2005-11-16 EP EP05811167.5A patent/EP1814589B1/en not_active Not-in-force
- 2005-11-16 JP JP2007541954A patent/JP5569949B2/ja not_active Expired - Fee Related
- 2005-11-16 EP EP10179145A patent/EP2292269A3/en not_active Withdrawn
- 2005-11-16 CN CN201310257884.4A patent/CN103316019B/zh not_active Expired - Fee Related
- 2005-11-16 WO PCT/EP2005/056023 patent/WO2006053884A1/en active Application Filing
- 2005-11-16 BR BRPI0517847-9A patent/BRPI0517847A/pt not_active IP Right Cessation
- 2005-11-16 MX MX2007006045A patent/MX2007006045A/es active IP Right Grant
- 2005-11-16 CN CN2005800395147A patent/CN101060860B/zh not_active Expired - Fee Related
- 2005-11-16 AU AU2005305882A patent/AU2005305882B2/en not_active Ceased
- 2005-11-16 US US11/791,242 patent/US20080255074A1/en not_active Abandoned
- 2005-11-16 CA CA2585317A patent/CA2585317C/en not_active Expired - Fee Related
-
2007
- 2007-04-23 IL IL182768A patent/IL182768A/en not_active IP Right Cessation
-
2012
- 2012-05-30 JP JP2012123266A patent/JP2012211145A/ja active Pending
-
2013
- 2013-04-18 US US13/865,259 patent/US20130231316A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1173330A (zh) * | 1996-06-19 | 1998-02-18 | 阿克佐诺贝尔公司 | 含米尔塔扎平和一种或多种选择性5-羟色胺再摄取抑制剂的药物组合物 |
WO2003037354A1 (en) * | 2001-10-26 | 2003-05-08 | Akzo Nobel N.V. | USE OF (11β, 17β)-11-(1,3-BENZODIOXOL-5-YL)-17-HYDROXY-17-(1-PROPYNYL)-ESTRA-4,9-DIEN-3-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER |
WO2004030618A2 (en) * | 2002-09-24 | 2004-04-15 | Combinatorx, Incorporated | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
Also Published As
Publication number | Publication date |
---|---|
CN103316019A (zh) | 2013-09-25 |
AU2005305882A1 (en) | 2006-05-26 |
US20130231316A1 (en) | 2013-09-05 |
EP2292269A3 (en) | 2011-08-10 |
JP2012211145A (ja) | 2012-11-01 |
WO2006053884A1 (en) | 2006-05-26 |
IL182768A0 (en) | 2007-07-24 |
EP1814589A1 (en) | 2007-08-08 |
MX2007006045A (es) | 2007-06-13 |
AU2005305882B2 (en) | 2011-07-14 |
CA2585317C (en) | 2015-02-24 |
EP1814589B1 (en) | 2015-04-15 |
IL182768A (en) | 2015-10-29 |
CA2585317A1 (en) | 2006-05-26 |
JP5569949B2 (ja) | 2014-08-13 |
CN101060860A (zh) | 2007-10-24 |
US20080255074A1 (en) | 2008-10-16 |
CN103316019B (zh) | 2015-10-28 |
BRPI0517847A (pt) | 2008-10-21 |
JP2008520625A (ja) | 2008-06-19 |
EP2292269A2 (en) | 2011-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Drewe et al. | A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients | |
McDougle | Update on pharmacologic management of OCD: agents and augmentation | |
KR101288172B1 (ko) | 항우울제 제조에서 20(s)-프로토파낙사다이올의 용도 | |
Wolfe et al. | Research update on serotonin function in bulimia nervosa and anorexia nervosa | |
JP2003521498A (ja) | ストレス治療用の組成物 | |
JP2003095979A (ja) | ヒスタミンレセプターアンタゴニストの組み合わせを用いる上気道アレルギー性応答の処置 | |
BR112017023088B1 (pt) | Compostos agonistas do receptor 5-ht2c, composição farmacêutica,seu processo de preparação e seus usos | |
JPH04501413A (ja) | タバコの禁断症状を処置する組成物 | |
WO2022115798A2 (en) | Compositions and methods for treating migraine | |
CN101562993A (zh) | 包含鼠尾草酚和/或迷迭香酚的膳食和药物组合物及其用途 | |
JP2005533788A (ja) | Pdeiv阻害剤および抗うつ薬または不安解消薬の組み合わせによるうつ病および不安の治療 | |
Fletcher et al. | The involvement of 5‐hydroxytryptaminergic and dopaminergic mechanisms in the eating induced by buspirone, gepirone and ipsapirone | |
CN101060860B (zh) | 用于治疗抑郁症的包含选择性5-羟色胺再摄取抑制剂和糖皮质激素受体拮抗剂的药物组合 | |
Steiner et al. | Luteal phase and symptom-onset dosing of SSRIs/SNRIs in the treatment of premenstrual dysphoria: clinical evidence and rationale | |
AU2021359134A1 (en) | Compositions and uses thereof | |
AU2011236053B2 (en) | Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression | |
US20240000716A1 (en) | Oral Dosage Forms Comprising a Hops Extract | |
Samuels et al. | Pharmacological treatment of dementia: a review | |
KR20090059326A (ko) | 혼합 생약재 추출물을 유효성분으로 하는 알코올 의존증의예방 및 치료용 조성물 | |
Berger et al. | Cholinergic drugs as diagnostic and therapeutic tools in affective disorders | |
Rosenberg | Selective serotonin-reuptake inhibitors | |
US20230390243A1 (en) | Compositions and Uses Thereof | |
Ayd | Mianserin (GB 94): a new tetracyclic antidepressant | |
CN101171011B (zh) | 用于治疗食欲紊乱的含有1-(3-氯苯基)-3-烷基哌嗪的药物组合物 | |
UA120895C2 (uk) | Фармацевтична композиція у формі сиропу для лікування алергічних захворювань |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Holland Applicant after: N.V. Organon Address before: Holland Applicant before: N.V. ORGANON |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: ORGANON NV TO: MSD OS CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: MERCK SHARP + DOHME CORP. Free format text: FORMER OWNER: ORGANON BIOLOGICAL NETHERLANDS CO., LTD. Effective date: 20131011 Owner name: ORGANON BIOLOGICAL NETHERLANDS CO., LTD. Free format text: FORMER OWNER: MSD OUSI CO., LTD. Effective date: 20131011 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20131011 Address after: Haarlem Patentee after: MERCK SHARP & DOHME B.V. Address before: Haarlem Patentee before: Organon biological science Holland Co.,Ltd. Effective date of registration: 20131011 Address after: Haarlem Patentee after: Organon biological science Holland Co.,Ltd. Address before: Holland Patentee before: N.V. Organon |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130717 Termination date: 20171116 |
|
CF01 | Termination of patent right due to non-payment of annual fee |